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أثر نوع بدلة الصمام على النتائج القلبية الوعائية ملرضى الغسيل املزمن
جميل حاج �ساهني، زياد �سعيد دحدوح، طوين عبدامل�سيح
الكلوي.  بالغ�سيل  الذين يعاجلون  الكلوي  الف�سل  البديل يف مر�سى  ال�سمام  اإختيار  اإىل  املر�سدة  البيانات  تعار�ض يف  امللخ�ض: يوجد 
قررنا البحث، بعد مراجعة الدرا�سات املتعلقة املن�سورة، عن اأف�سل بديل لل�سمام يف مر�سى الغ�سيل الكلوي املزمن. جمموعة 9 درا�سات 
اإ�ستعادية قارنت نتائج نوعني من ال�سمامات، اأظهرت نتائج مت�سابهة واأبرزت اآمان اإ�ستخدام ال�سمامات البيولوجية يف مر�سى الغ�سيل 
الكلوي املزمن. لقد تغريت معايري اإختيار ال�سمامات البديلة عرب الزمن، لفرتة طويلة كان يعتقد اأن �سمامات الأن�سجة تخ�سع للتكل�ض 
املبكر ب�سبب خلل اإ�ستقالب الكال�سيوم يف مر�سى الف�سل الكلوي يف املراحل املتاأخرة. النزف كان اأكرث امل�ساعفات املتعلقة بال�سمامات 
وميثل اأكرب ق�سور لإ�ستخدام ال�سمامات امليكانيكية. اأو�سحت درا�ستان اأن زرع ال�سمامات امليكانيكية كان له ميزة البقاء لعمر اأطول 
للمر�سى. ميكن الإ�ستنتاج باأن جراحني القلب يجب األ يرتددوا يف زرع ال�سمامات البيولوجية لأن تلف هذه ال�سمامات يعترب حالت 
فردية وغري منت�رش يف هذه املجموعة من املر�سى. اإختيار ال�سمام البديل يجب اأن يكون مبنى على نف�ض املعايري املطبقة على املر�سى 
الذين ل يعانون من الف�سل الكلوي. 
مفتاح الكلمات: غ�سيل كلوي، بدلت ال�سمام القلبي، بدلت بيولوجية، بدلت وغر�سات، حتليل.
abstract: There is conflicting evidence guiding valve prosthesis selection in patients with end-stage renal disease 
on dialysis. We sought to determine, after reviewing the relevant literature, the best valve substitute in patients 
on chronic dialysis. A total of 9 retrospective studies compared the outcomes of two valves, showing similar 
results and highlighting the safety of implanting bioprostheses in patients on chronic dialysis. Standards of valve 
selection have changed over time; it has long been believed that tissue valves undergo premature degeneration due 
to calcium metabolism derangements in patients with end-stage renal disease. Bleeding was the most common 
valve-related complication and represented a major drawback of mechanical valves. Two studies demonstrated 
a survival advantage in favour of mechanical prostheses. It can be concluded that surgeons should not hesitate 
to implant bioprostheses because singular valve decomposition would be uncommon in this patient population. 
Prosthesis selection should be based on the same criteria as those used for non-dialysis patients. 
Keywords: Renal Dialysis; Heart Valve Prostheses; Bioprostheses; Prostheses and Implants, analysis.
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The best valve substitute in patients on chronic dialysis undergoing valve replacement surgery is still a matter of 
ongoing debate. When choosing a mechanical valve, 
the preservation and durability of the biological 
components of a bioprosthesis should be weighed 
against the risk of life-threatening bleeding or major 
thrombo-embolism generally linked to the use of 
life-long anticoagulants.
Methods
The standards of valve selection have changed 
over time. It has long been believed that tissue 
valves undergo premature degeneration due to the 
derangements in calcium metabolism in patients 
with end-stage renal disease. This is based on a 
report by Lamberti who described two patients 
with accelerated degeneration of their bioprosthetic 
valves.1
In 1998, American College of Cardiology/
American Heart Association (ACC/AHA) 
guidelines recommended the use of mechanical 
valves in patients on dialysis. However, 7 
retrospective studies from North America and two 
from Japan specifically compared the outcomes of 
the two valves and showed similar results, 
highlighting the safety of implanting a bioprosthesis 
in patients on chronic dialysis.2–10 Recently, 
accumulating data supporting the very low 
incidence of rapid tissue valve degeneration in 
dialysis patients has been taken into consideration, 
and the 2006 ACC/AHA practice guidelines do not 
specify the best choice for valve replacement in 
dialysis patient. 
To provide the best evidence to address this 
issue, a literature review of the most relevant 
studies was performed using PubMed. The most 
relevant papers treating this problem are listed and 
summarised in Table 1.
Results
Lucke et al. reviewed 19 consecutive patients with 
end-stage renal disease from a single institution 
who had undergone aortic, mitral or aorto-
mitral valve replacement.2 The mechanical valve 
patients (n = 10) had a significantly higher rate of 
postoperative cerebrovascular events or bleeding 
complications than the bioprosthetic patients (n 
= 9). No subsequent reoperations were required 
for biological valve failure. The overall estimated 
Kaplan-Meier survival was 42 ± 14% at 60 months.
Kaplon et al., from the Cleveland Clinic 
Foundation, found comparable results for both 
types of valves when reviewing 42 patients 
on preoperative dialysis undergoing valve 
replacements;3 17 received mechanical valves and 
25 received a bioprosthesis. Of the 25 fitted with 
bioprosthetic valves, 4 required reoperation with 
one admitted for mitral bioprosthesis degeneration. 
Prosthetic valve-related complications and survival 
were similar for both mechanical and bioprosthetic 
valves. 
Herzog et al. reviewed the US Renal Data System 
database. Dialysis patients (n = 5,858) hospitalised 
for heart valve replacement surgery were the 
subjects of the study.4 Tissue valves were used in 
881 patients (15%). Aortic valve replacement was 
performed in 58%, mitral valve replacement in 32%, 
and combined aortic and mitral valve replacement in 
10%. There was no significant difference in survival 
related to type of valve. The two-year survival rate 
was 39.7 ± 3.5% with tissue valves versus 39.7 ± 1.4% 
for non-tissue valves.
Brinkman et al. found that the choice of valve 
substitute used in dialysis patients did not influence 
early and late survival; however, with a mechanical 
valve there were a six-fold higher incidence of late 
bleeding or stroke in patients on dialysis.5
 Chan et al. investigated the results of 69 valve 
replacements in patients with end-stage renal 
disease.6 One case of structural valve deterioration 
(SVD) occurred in the bioprosthesis group, 
requiring reoperation at 95 months after surgery. 
A survival advantage was observed in favour of 
mechanical prostheses at 5 years. Nevertheless, 
composites of complications were similar between 
the two groups. 
Toole et al. reviewed 50 dialysis patients 
undergoing left-sided valve replacement.7 The 
tissue valve group had significantly higher Kaplan-
Meier freedom from valve-related morbidity and 
mortality at three years. Freedom from reoperation 
was not significantly different.
 Filsoufi et al. analysed data from 155 patients 
with renal failure who underwent left-sided valve 
surgery, of whom 108 patients were on chronic 
dialysis.8 Regarding the type of prosthesis, hospital 
mortality and freedom from reoperation were 
similar in patients with mechanical and biological 
valves. 
Umezu et al. analysed data from 63 consecutive 
dialysis patients who underwent valvular surgery.9 
The mechanical group had a higher rate of bleeding 
events but there was no SVD up to the 5-year follow-
up. However, both mechanical and bioprosthetic 
valve patients had similar survival and event-free 
rates. 
Tanaka et al. performed a retrospective review on 
73 aortic valve replacements for dialysis patients.10 
No SVD of the bioprosthesis was seen in this series. 
Valve-related complications were documented in 
12 of 44 patients in the mechanical valve group and 
in 2 of 21 patients in the bioprosthesis group. The 
all-cause survival rate of patients with bioprosthesis 
was significantly worse than that of patients with 
mechanical valves.
Discussion
A major concern of cardiovascular surgical teams 
when implanting a bioprosthesis in a patient on 
dialysis is SVD, and many papers have been written 
on the subject. However, none of the studies have 
been randomised controlled trials. Only 4 cases of 
SVD requiring reoperation (at 10-96 months after 
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the initial valve replacement surgery) were identified 
from the 9 retrospective studies.2–10 Of note, the 
mean follow-up of each study was relatively short; 
therefore, definite conclusions about the long-
term performance of tissue valves in this patient 
population cannot be drawn. 
Bleeding was the most common valve-related 
complication, representing a major drawback of 
mechanical valves. Thromboembolic events were 
reported in 35 patients, of whom 31 received 
mechanical prostheses. A total of 7 of the 9 studies 
did not demonstrate a survival difference according 
to prosthesis type. The remaining two studies 
demonstrated a survival advantage in favour of 
mechanical prostheses.6,10 However, patients who 
received bioprosthetic valves were older and more 
likely to have had a previous myocardial infarction 
or to have received concomitant coronary artery 
bypass grafting. 
Recently, Chan et al. performed a systematic 
review and meta-analysis of valve replacement in 
patients on dialysis.11 In 9 studies published from 
1997 to 2010, no difference in survival was observed 
between the valve types (bioprosthesis versus 
mechanical prosthesis; hazard ratio 1.3, 95% CI 1.0–
1.9, P = 0.09). However, bioprosthetic valves were 
associated with fewer valve-related complications 
compared with mechanical prostheses (odds ratio 
0.4, 95% CI 0.2–0.7, P = 0.002). They concluded 
that there was no survival difference following 
valve replacement with either bioprosthesis or 
mechanical prosthesis in patients on dialysis.
More recently, Pai et al. published their review 
on the same subject. They found 8 relevant 
retrospective studies and concluded that there was 
no significant difference in the results and survival 
between patients receiving a mechanical and those 
receiving a bioprosthetic valve.12 However, bleeding 
complications were more common with mechanical 
valves.
Conclusion
It can be concluded that dialysis patients after 
cardiac valve replacement suffer poor midterm 
and long-term survival rates. Therefore, due to the 
limited life expectancy of these patients, physicians 
should not hesitate to implant bioprosthetic valves 
because SVD will be uncommon in this patient 
population. Prosthesis selection should be based on 
the same criteria used for non-dialysis patients.
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